Amendments to the Claims

1. (Currently Amended) A method for treating cancer in a cancer patient comprising:

administering to the patient a water-insoluble 20(S)-camptothecin for a period of time during which 5-fluorouracil is not being administered to the patient and is not present in a pharmaceutically active form in the patient; and

administering 5-fluorouracil to the patient, wherein the period of time during which 5-fluorouracil is not being administered to the patient is at least 1 day, and the water insoluble 20(S) camptothecin is 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin.

2. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day before 5-fluorouracil is administered.

3. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days before 5-fluorouracil is administered.

4. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days before 5-fluorouracil is administered.

5. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days before 5-fluorouracil is administered.

6. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days before 5-fluorouracil is administered.

7. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 1 and 90 days before 5-fluorouracil is administered.

8. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before 5-fluorouracil is administered.

9. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before 5-fluorouracil is administered.

10. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before 5-fluorouracil is administered.

11. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 5 and 90 days before 5-fluorouracil is administered.

12. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day after 5-fluorouracil is administered.

13. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days after 5-fluorouracil is administered.

14. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days after 5-fluorouracil is administered.

15. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days after 5-fluorouracil is administered.

16. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days after 5-fluorouracil is administered.

17. (Canceled)

18. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after 5-fluorouracil is administered and is also administered within 2 days of when 5-fluorouracil is administered.

19. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after 5-fluorouracil is administered and is also administered within 3 days of when 5-fluorouracil is administered.

20. (Previously Presented) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after 5-fluorouracil is administered and is also administered within 4 days of when 5-fluorouracil is administered.

21. (Previously Presented) A method according to claim 1 wherein the patient has pancreatic cancer.

22. (Canceled)

23. (Original) A method according to claim 1 wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

24. (Canceled)

25. (Previously Presented) A method according to claim 1 wherein the patient has cancer selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer.

26-53. (Canceled)